Abstract:
The invention related to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren. Inter alia, the invention relates to a process for the manufacture of a compound of the formula (I) or a salt thereof, wherein R1 as well as Act are as defined in the specification, and processes of manufacturing this compound as well as intermediates in this process.
Abstract:
One aspect of the present invention relates to quinine-based and quinidine-based catalysts. Another aspect of the invention relates to a method of preparing a derivatized quinine-based or quinidine-based catalyst comprising 1) reacting quinine or quinidine with 5 base and a compound that has a suitable leaving group, and 2) converting the ring methoxy group to a hydroxy group. Another aspect of the present invention relates to a method of preparing a chiral, non-racemic compound from a prochiral electron-deficient alkene or azo compound or prochiral aldehyde or prochiral ketone, comprising the step of: reacting a prochiral electron-deficient alkene or azo compound or prochiral aldehyde or prochiral 10 ketone with a nucleophile in the presence of a catalyst; thereby producing a chiral, non racemic compound; wherein said catalyst is a derivatized quinine or quinidine. Another aspect of the present invention relates to a method of kinetic resolution, comprising the step of reacting racemic chiral alkene with a nucleophile in the presence of a derivatized quinine or quinidine. ® KIPO & WIPO 2007
Abstract:
본 발명은 간질, 기절 발작, 신경변성질환, 우울증, 불안증, 공황, 통증, 신경병리학적 질환, 과민성 대장 증후군(IBS)같은 위장질환 및 염증, 특히 관절염의 치료에 유용한 시클릭 아미노산계열의 신규한 화합물에 관한 것이다. 화합물의 제조방법, 및 최종화합물제조에 유용한 신규한 중간물질뿐만 아니라, 본 발명의 화합물을 함유하는 제약학적 조성물도 포함된다. 아미노산, 시클릭아미노산, 제약학적 조성물
Abstract:
본 발명에 따른 키랄성 (R)-롤리프람 전구체의 제조 방법은 이작용성 키랄 촉매의 존재 하에 3-(사이클로펜톡시)-4-메톡시페닐 나이트로 알킨과 말로네이트를 비대칭 마이클 반응시키는 단계를 포함한다. 이에 따라, 전이금속을 포함하지 않는 유기물 촉매를 이용하여 저렴하고, 인체에 유해하지 않으며 환경오염을 유발하지 않는 물 혹은 수용액과, 이들의 유기용매 혼합용액 존재 하에서 높은 광학 선택성과 반응성으로 키랄성 (R)-롤리프람 전구체를 합성할 수 있다.
Abstract:
A compound represented by the general formula (1') or a salt thereof; and a therapeutic or prophylactic agent for a glucocorticoid-related condition or an 11FHSD1 inhibitor comprising the compound of the salt thereof: (1') wherein the ring A, R2, R3, R4 and X are as defined in the description.
Abstract:
A process for producing an asymmetric compound (IV), characterized by causing a compound (II) to add a nucleophilic reagent (III) through conjugate addition in the presence of an asymmetric urea compound (I). Also provided is a nonmetallic asymmetric catalyst capable of realizing asymmetric conjugate addition reaction which attain high yield and are highly stereoselective. The process is an advantageous process for producing an asymmetric compound by an asymmetric conjugate addition reaction in which the catalyst is used. [In the formulae, X represents oxygen or sulfur; C*, C**, and C*** each indicates asymmetric carbon; R1, R2, R4, R5, R8, R9, and R10 each represents optionally substituted lower alkyl, etc., provided that, for example, R4 and R5 may be bonded to each other to form an optionally substituted homocycle, etc.; R3 represents optionally substituted aryl, etc.; R6 and R7 each represents hydrogen, etc.; Nu represents -CR16(COR17)(COR 18) (wherein R16, R17, and R18 each represents optionally substituted lower alkyl, etc.), etc.; and EWG represents an electron-withdrawing group.]
Abstract:
본원은, 알칼리 금속 또는 알칼리 토금속 이온을 포함하는 염기성 촉매의 존재 하에 진행되는 첨가 반응 또는 축합 유기 반응을 위한 상전이 (phase transfer) 촉매에 있어서, 상기 상전이 촉매는 산소 작용기를 함유하는 그래핀 옥사이드를 포함하고, 상기 첨가 반응 또는 축합 유기 반응 중 상기 산소 작용기와 상기 알칼리 금속 또는 알칼리 토금속 이온의 결합에 의해 상기 첨가 반응 또는 축합 유기 반응이 촉진되는 것인, 그래핀 옥사이드를 포함하는 상전이 촉매에 관한 것이다.
Abstract:
A method of synthesizing a chiral compound having a quarternary carbon atom bearing diastereotopic groups from (a) a nitroolefin and (b) an alpha-substituted beta-dicarbonyl or an equivalent compound having an acidic C-H moiety compound is disclosed. A subsequent intramolecular reaction between one of the substituents comprising the stereogenic carbon atom and one of the diastereotopic groups comprising the quaternary carbon atom creates a new compound having two contiguous stereogenic centers, one of which is quaternary, with control over the relative stereochemistry.